Zoll Medical, an Asahi Kasei company, announced today that the FDA has approved its next-gen Remedē EL-X implantable neurostimulation system to treat severe sleep apnea. Zoll acquired the technology through its acquisition of Respicardia in April. Improvements to the new Remedē EL-X include: 40% longer average battery life versus the previous version; Three-fourths the size […]
Respicardia
DTW Podcast: How is Zimmer Biomet waging the ortho data war? Do medical devices carry physics-based biases?
In this week’s DeviceTalks Weekly Podcast, Liane Teplitsky, vice president and general manager of worldwide robotics at Zimmer Biomet, shares her excitement for the burgeoning data business emerging in orthopedics. Teplitsky, an engineer who built her medtech career in cardiac R&D and sales at St. Jude and Abbott, walks us through the interconnected offerings of […]
Zoll Medical acquires Respicardia
Zoll Medical said today that it has acquired Respicardia and its neurostimulation tech for treating sleep apnea. The financial terms of the deal were not disclosed. Respicardia makes implantable neurostimulators to treat moderate to severe central sleep apnea (CSA). The system is FDA approved to treat severe CSA in adult patients with reduced cardiac function. […]
Medicare might cover more cutting-edge medtech and pay more for it, too
The Centers for Medicare and Medicaid Services (CMS) said today it wants to give Medicare patients better access to cutting-edge medical devices, and that it’s willing to pay more for them beginning in fiscal year 2020. In its proposed rule, CMS said it might pay more for “certain transformative new devices” for inpatients through a […]
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
Respicardia launches Remedē system, taps Sommerness as CEO
Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to […]
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Zoll leads $59m Respicardia funding round
Respicardia said today it closed a $58.5 million financing round led by Zoll Medical to support commercialization efforts related to its Remede transvenous implantable neurostimulation system designed to treat patients with central sleep apnea. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the […]
Respicardia wins FDA nod for Remedē central sleep apnea neurostim device
Respicardia said today that it won FDA approval for its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea. Central Sleep Apnea occurs when the brain fails to control breathing during sleep, unlike the more common obstructive sleep apnea which consists of a partially collapsed airway which causes pauses in breathing, […]
Study: Respicardia neurostim implant shows promise in treating central sleep apnea
An implanted neurostimulator developed by Respicardia has been shown to significantly improve symptoms of central sleep apnea without serious side effects, according to a new study from the Ohio State University. Data from the study was presented at the European Society of Cardiology Congress in Rome and was published today in The Lancet. Central sleep […]
Sorin drops $20m on stake in Respicardia
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
